Research has shown that a novel antibody generated to target an ‘essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).
ImmunoBrain Checkpoint Inc.today announced the appointment of James M. Mackay , Ph.D., to the Board of Directors. Mackay brings decades of biopharma leadership experience to the Company’s Board.
Viseon Inc. Announces Commercial Rollout and Initial Clinical Use of the 4K MaxView ® System for Advanced Digital Visualization during Minimally Invasive Spine Surgery.
Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from its PROCLAIM trial, published in European Urology Oncology, showing that almost half of prostate cancer patients with clinically actionable pathogenic/likely pathogenic germline variants (PGVs) could be missing out on genetics-informed care due to restrictive criteria for genetic testing.
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer Read More »
Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane’s effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.
ExThera Medical Corporation announces it has received simultaneous certification per Medical Device Single Audit Program (MDSAP) and International Organization for Standardization (ISO 13485) requirements.
AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.
AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors Read More »
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for cardiovascular machine learning-based notification software.
OnCusp Therapeutics announced today the clearance of its Investigational New Drug (IND) Application for CUSP06 by the U.S. Food and Drug Administration (FDA).
RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations Read More »
